Viridian Therapeutics Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Viridian Therapeutics non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

-35.6%

Rendimento del riacquisto

Rendimento totale per gli azionisti	-35.6%
Rendimento futuro dei dividendi	0%
Crescita dei dividendi	n/a
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Rapporto di remunerazione	n/a

Aggiornamenti recenti su dividendi e riacquisti

Nessun aggiornamento

Recent updates

We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate

Nov 14

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Sep 12

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

May 15

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

Apr 18

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Jan 08

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Sep 09

Viridian Therapeutics board compensation committee approves inducement grants

Sep 02

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Aug 22

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di VRDN siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di VRDN siano aumentati.

Rendimento dei dividendi rispetto al mercato

Viridian Therapeutics Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di VRDN rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (VRDN)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.3%
Media del settore (Biotechs)	2.3%
Analista previsionale (VRDN) (fino a 3 anni)	0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di VRDN rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di VRDN rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di VRDN per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché VRDN non ha segnalato alcun pagamento.

Viridian Therapeutics Dividendi e riacquisti

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Recent updates

We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, President & Director recently bought US$499k worth of stock

New major risk - Shareholder dilution

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Price target increased by 7.5% to US$37.81

Viridian Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $225 million.

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

New minor risk - Share price stability

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Viridian Therapeutics, Inc. Announces Positive Clinical Activity Data for VRDN-001

Consensus revenue estimates fall by 19%

First half 2024 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year

Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?

Consensus revenue estimates increase by 21%

Price target decreased by 7.3% to US$36.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New minor risk - Share price stability

New major risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 15%, EPS upgraded

Price target decreased by 8.0% to US$40.07

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Price target decreased by 10% to US$41.36

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Executive Changes

Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 18%

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?

President recently bought US$101k worth of stock

Consensus revenue estimates fall by 35%

President recently bought US$160k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Price target increased by 9.1% to US$47.08

Chief Medical Officer exercised options and sold US$708k worth of stock

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Consensus revenue estimates increase by 162%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market

Viridian Therapeutics board compensation committee approves inducement grants

Consensus forecasts updated

An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Price target increased to US$39.22

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti